AAT augmentation therapy, as the only available therapeutic option with a causal approach, is usually administered in the late stages of the disease and therefore does not contribute to the prevention of lung disease, but only serves to slow the progression of the disease. This evidence concerns the gene SERPINA1 and lung disorder.